AzTrials
AzTrials

MenopauseEMBRACENCT07005648

Brazilian Registry of Menopausal Health

An observational study of Menopause, run by Science Valley Research Institute at 1 site in Brazil.

Recruiting

Looking for participants now. Contact the study team or a site below to ask about taking part.

Sites and contacts
Official record
Search all trials

Trial summary

The Brazilian Registry of Menopausal Health is a national study aimed to better understand the health and quality of life of participants aged 35 to 65 who are in the menopausal transition or postmenopausal phase, including cisgender women and transgender men. Read more about this study

Who is it for?
Ages 35 to 65 yearsHealthy volunteers can take part
Conditions the study is for
Menopause
How many people
1,592 participants
Where
1 siteBrazil
Study dates
11 Sep 2026to 11 Sep 2027
Phase
Observational
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 35 to 65 years
  • All sexes
  • Healthy volunteers accepted
  • Adult, Older adult

Study population: Cisgender women or transgender men who have not undergone surgical or hormonal reassignment of secondary sexual characteristics, aged between 35 and 65 years, seeking outpatient care in public or private healthcare services.

Who may be able to join

  • Women aged between 35 and 65 years attending medical consultation at public and private outpatient health services;
  • Ability to confirm voluntary participation and sign the Informed Consent Form

Who cannot join

  • Inability to respond to the interview for any reason
  • Suspected or confirmed pregnancy
  • Lactation
  • Uncontrolled diabetes
  • Uncontrolled arterial hypertension
  • Uncontrolled thyroid disorders
Show all 11Show fewer
  • Grade 3 obesity, defined by a BMI equal to or greater than 40.0 kg/m²
  • Diagnosis of psychiatric disorders that may compromise participation in the interview
  • Previous hysterectomy
  • Previous oophorectomy
  • Current use of illicit drugs

Trial locations and contacts

1 site in 1 country. Contact the study team or a site near you to ask about taking part.

Brazil1 site, 1 recruiting
  • Centro de Pesquisa Unidade Morumbi - Science Valley Research Institute

    São Paulo, São Paulo, 05615-190

    Daniele Komar, +55 (11) 4040-8670, daniele.komar@svriglobal.com

    Fabiane B de Souza, MD

    Recruiting

Other trials in Brazil

About this study

Official title: Population-based Cross-sectional Observational Study for a Brazilian Registry of Menopausal Women and Associated Factors Related to Clinical Profile, Socioeconomic Aspects, Social Disparities, Access to Healthcare, Quality of Life, and Knowledge About Menopause - EMBRACE Study (Endrocrine Mapping in the Broad Range Of Aging and Climateric Experiences)

The Brazilian Registry of Menopausal Health is a national study aimed to better understand the health and quality of life of participants aged 35 to 65 who are in the menopausal transition or postmenopausal phase, including cisgender women and transgender men.

The study's hypothesis is that significant regional and socioeconomic disparities influence individuals' health, knowledge, and perception of menopause.

Read the detailed description

The Brazilian Registry of Menopausal Health, called EMBRACE STUDY (Endrocrine Mapping in the Broad Range Of Aging and Climateric Experiences), is an observational, cross-sectional, population-based study conducted with the objective of characterizing the epidemiological aspects of the Brazilian population during the menopausal transition and postmenopause, as well as the factors associated with clinical profiles and symptomatology, socioeconomic conditions, social inequalities, access to healthcare services, quality of life, and knowledge about menopause.

The study will include cisgender women and transgender men who have not undergone surgical or hormonal gender reassignment of secondary sexual characteristics, aged between 35 and 65 years, who seek outpatient care in public or private healthcare services. Data about transgender men will be collected for exploratory purposes.

A total of 1,592 participants will be enrolled, with 617, 509, and 466 participants in the respective age groups of 35-44, 45-54, and 55-65 years, proportionally stratified across the 27 state capitals of Brazil. These age groups will be used solely for the purpose of sample stratification. Data will be collected during a routine outpatient visit, without requiring additional study visits. Information will be obtained through a single interview, routine test results, and self-reported questionnaires.

A subgroup of 150 participants will undergo non-invasive instrumental and biometric assessments and high-resolution digital photography as an optional assessment of skin and hair physiology. Selected study centers will be chosen based on infrastructure and logistical feasibility, considering regional differences in temperature and humidity that may influence skin and hair characteristics.

Conditions
Menopause
Keywords
Menopause, Post Menopause, Menopause Transition, Climateric

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

Study groups in NCT07005648
Study groupRoleWhat they receive
617 participants = 35 to 44 years oldNot described
509 participants = 45 to 54 years oldNot described
466 participants = 55 to 65 years oldNot described

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Proportion of participants aged 35 to 65 classified as being in the menopausal transition or postmenopause.

    Definition of menopausal status. Premenopause: regular menstrual cycles, corresponding to the reproductive period preceding menopause; Menopausal transition: characterized by irregular menstrual cycles and amenorrhea for less than 12 months.

    Postmenopause: amenorrhea for more than 12 months.

    Measured: Day 1 (during the medical appointment)

Secondary outcomes (14)
  1. Proportion of participants in each menopausal status.

    Premenopause; Menopausal transition; Postmenopause.

    Measured: Day 1 (during the medical appointment)

  2. Characterization of the clinical profile.

    This outcome measure includes a structured assessment of variables related to the participant's gynecologic and clinical history: age at menarche, menstruation status, date of last menstruation, age at last menstruation, personal medical history, and comorbidities.

    These variables and the summary statistics (when applicable) will be aggregated to produce a standardized clinical profile report for each participant.

    Measured: Day 1 (during the medical appointment)

  3. Characterization of knowledge and self-perception of menopause.

    This outcome measure includes a structured assessment of participants' understanding and personal perspective regarding menopause. The evaluation comprises the following elements: perception of menopause, definitions of menopause, history of hormone therapy (HT) use, perception and expectations regarding HT, and perceived impact of HT on menopause experience.

    These variables will be aggregated to generate a descriptive profile of knowledge and self-perception of menopause for each participant.

    Measured: Day 1 (during the medical appointment)

  4. Characterization of the anthropometric and physiological profile.

    This outcome measure includes anthropometric and physiological parameters: weight (in kilograms), height (in centimeters), body mass index (BMI, calculated as weight/height² in kg/m²), waist circumference (in centimeters), hip circumference (in centimeters), and blood pressure (in mmHg). These variables will be aggregated to generate an anthropometric profile for each participant, allowing for descriptive and comparative analysis of body composition and cardiovascular markers.

    Measured: Day 1 (during the medical appointment)

  5. Characterization of General Health Profile.

    This outcome measure includes a structured assessment of the participant's self-reported health status and medical history. It comprises self-perception of health, history of surgeries, pre-existing comorbidities, and current use of medications.

    These variables will be aggregated into a descriptive health profile for each participant.

    Measured: Day 1 (during the medical appointment)

  6. Characterization of Laboratory Profile.

    This outcome measure includes laboratory test results related to metabolic, hormonal, and glycemic profiles. The following biomarkers will be collected: Thyroid-Stimulating Hormone (TSH), Free Thyroxine (T4), Luteinizing Hormone (LH), Follicle-Stimulating Hormone (FSH), Estradiol, Progesterone, Total Cholesterol, Low-Density Lipoprotein Cholesterol (LDL), High-Density Lipoprotein Cholesterol (HDL), Triglycerides, Fasting Glucose, and Glycated Hemoglobin. These results will be aggregated to form a laboratory profile for each participant.

    Measured: Day 1 (during the medical appointment)

  7. Characterization of the social profile.

    This outcome measure includes a structured assessment of socioeconomic profile, access to healthcare and employment status. The variables assessed in socioeconomic classification are according to the Brazilian Association of Companies and Research (ABEP) and were used to analyze the socioeconomic level, which includes the educational level of the head of household, and includes questions about family income, possession of public items and services offered in its residence. These data will be aggregated to generate a social profile for each participant.

    Measured: Day 1 (during the medical appointment)

  8. Characterization of the demographic profile.

    This outcome measure includes key demographic variables relevant to reproductive and social background: marital status, education level, race/skin color, number of children, number of pregnancies, and number of abortions. These data will be aggregated to produce a comprehensive understanding of the demographic participant profile.

    Measured: Day 1 (during the medical appointment)

  9. Characterization of lifestyle profile.

    This outcome measure includes a structured assessment of lifestyle-related behaviors. The variables assessed are history of smoking, physical activity practice, alcohol consumption, and use of psychoactive substances. These variables will be aggregated to produce a lifestyle profile for each participant.

    Measured: Day 1 (during the medical appointment)

  10. Total score and quantitative domains of the QSM/WHQ questionnaire [Women's Health Questionnaire (WHQ) / Questionário da Saúde da Mulher (QSM); applicable to women aged 45 to 65 years].

    Women's health questionnaire (WHQ/QSM) is used to evaluate quality of life. This validated 36-item questionnaire measures changes in nine domains of physical and emotional health associated with the menopause transition. Analysis results in a score between 0.00 and 1.00, where higher scores are associated with worse symptomology and quality of life. A change of 0.10-0.20 is clinically meaningful.

    Measured: Day 1 (during the medical appointment)

  11. Total score and quantitative domains of the SF-36 questionnaire [36-Item Short-Form Health Survey].

    The SF-36 is a 36-item, 8-domain questionnaire used to assess overall health: physical functioning, role physical, role emotional, bodily pain, vitality, social functioning, mental health, and general health. Items are answered on Likert scales of varying lengths. Items from 8 domains contribute to the PCS. The summary scores range from 0 to 100, with higher scores indicating better levels of function and/or better health

    Measured: Day 1 (during the medical appointment)

  12. Total score and quantitative domains of the WPAI-GH questionnaire [WPAI-GH (Work Productivity and Activity Impairment - General Health)].

    The WPAI (Work Productivity and Activity Impairment) is questionnaire created as a patient-reported quantitative assessment. This questionnaire has 6 questions, which are used to calculate 4 types of scores; which are absenteeism (work time missed), presenteeism (reduced on the job effectiveness), work productivity loss (overall work impairment) and activity impairment. The scores are expressed in percentage with higher numbers indicating greater impairment and less productivity

    Measured: Day 1 (during the medical appointment)

  13. Classification of anxiety according to the GAD-7 questionnaire [Generalized Anxiety Disorder scale].

    The GAD-7 is a self-administered questionnaire that assesses generalized anxiety, composed of seven questions covering aspects such as excessive worry, difficulty controlling worry, irritability, muscle tension, fatigue, difficulty relaxing, and sleep problems. Each question is scored from 0 to 3, with a severity score ranging from 0 to 21. Cutoff points are ≥5 for mild anxiety, ≥10 for moderate anxiety, and ≥15 for severe anxiety.

    Measured: Day 1 (during the medical appointment)

  14. Classification of depression according to the PHQ-9 questionnaire [Patient Health Questionnaire-9 (PHQ-9)].

    The PHQ-9 is a self-administered questionnaire focused on depression, consisting of nine questions addressing aspects like diminished interest, depressed mood, fatigue, sleep issues, appetite changes, low self-esteem, difficulty concentrating, slowed movements or agitation, and suicidal thoughts. Each question is scored from 0 to 3, with a severity score from 0 to 27. Severe depression is indicated by a score >16.

    Measured: Day 1 (during the medical appointment)

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted5 Jun 2025
  2. Study start11 Sep 2026
  3. Primary completion11 Sep 2027 (estimated)
  4. Study completion11 Sep 2027 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Cohort
Time perspective
Cross-sectional
Enrolment
1,592 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT07005648
Sponsor's protocol ID
EMBRACE
Acronym
EMBRACE
Status last verified
Sep 2026
First submitted
24 Apr 2025
Last updated
1 Oct 2026
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
Undecided

Publications

  • Thurston RC, Joffe H. Vasomotor symptoms and menopause: findings from the Study of Women's Health across the Nation. Obstet Gynecol Clin North Am. 2011 Sep;38(3):489-501. doi: 10.1016/j.ogc.2011.05.006.

    PubMed 21961716
  • Flores VA, Pal L, Manson JE. Hormone Therapy in Menopause: Concepts, Controversies, and Approach to Treatment. Endocr Rev. 2021 Nov 16;42(6):720-752. doi: 10.1210/endrev/bnab011.

    PubMed 33858012
  • Mehta J, Kling JM, Manson JE. Risks, Benefits, and Treatment Modalities of Menopausal Hormone Therapy: Current Concepts. Front Endocrinol (Lausanne). 2021 Mar 26;12:564781. doi: 10.3389/fendo.2021.564781. eCollection 2021.

    PubMed 33841322
  • Davis SR, Taylor S, Hemachandra C, Magraith K, Ebeling PR, Jane F, Islam RM. The 2023 Practitioner's Toolkit for Managing Menopause. Climacteric. 2023 Dec;26(6):517-536. doi: 10.1080/13697137.2023.2258783. Epub 2023 Dec 1.

    PubMed 37902335
  • Oliveira GMM, Almeida MCC, Arcelus CMA, Neto Espindola L, Rivera MAM, Silva-Filho ALD, Marques-Santos C, Fernandes CE, Albuquerque CJDM, Freire CMV, Izar MCO, Costa MENC, Castro ML, Lemke VMG, Lucena AJG, Brandao AA, Macedo AVS, Polanczyk CA, Lantieri CJB, Nahas EP, Alexandre ERG, Campana EMG, Braganca EOV, Colombo FMC, Barbosa ICQ, Rivera IR, Kulak J, Moura LAZ, Pompei LM, Baccaro LFC, Barbosa MM, Rodrigues MAH, Albernaz MA, Decoud MSP, Paiva MSMO, Sanchez-Zambrano MB, Campos MDSB, Acevedo M, Ramirez MS, Souza OF, Medeiros OO, Carvalho RCM, Machado RB, Silva SCTFD, Rodrigues TCV, Avila WS, Costa-Paiva LHSD, Wender MCO. Brazilian Guideline on Menopausal Cardiovascular Health - 2024. Arq Bras Cardiol. 2024 Aug 16;121(7):e20240478. doi: 10.36660/abc.20240478. No abstract available. English, Portuguese.

    PubMed 39166619
  • Duralde ER, Sobel TH, Manson JE. Management of perimenopausal and menopausal symptoms. BMJ. 2023 Aug 8;382:e072612. doi: 10.1136/bmj-2022-072612.

    PubMed 37553173
  • Pompei LM, Bonassi-Machado R, Steiner ML, Pompei IM, de Melo NR, Nappi RE, Fernandes CE. Profile of Brazilian climacteric women: results from the Brazilian Menopause Study. Climacteric. 2022 Oct;25(5):523-529. doi: 10.1080/13697137.2022.2088276. Epub 2022 Jul 8.

    PubMed 35801642

Questions about this trial

What is this clinical trial studying?

An observational study of Menopause, run by Science Valley Research Institute at 1 site in Brazil.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 2 inclusion and 11 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: looking for participants now, as of the sponsor's last update on 1 Oct 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Brazil. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact Leandro Agati (+55 (11) 4468-8183, agati@svriglobal.com), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Proportion of participants aged 35 to 65 classified as being in the menopausal transition or postmenopause. (time frame: Day 1 (during the medical appointment)). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT07005648, which also lists 7 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 1 Oct 2026.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in